Skip to main content
Premium Trial:

Request an Annual Quote

Protein Design Labs to Acquire Eos Biotechnology

NEW YORK, Feb. 5 - Protein Design Labs will acquire Eos Biotechnology in an all-stock transaction valued at $37.5 million, the Fremont, Calif., company said yesterday.


The merger is expected to close in the first quarter of 2003, subject to regulatory approval.


Protein Design Labs develops therapeutic antibodies for cancer treatment and immunologic disorders. Eos Biotechnology, of South San Francisco, uses its proprietary genomics platform to identify novel disease targets and develop antibodies.


Click here for more information.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.